Search bioRxiv⌕ Search

Biology subjects

Dreyer, S.

Publications and source records attributed to Dreyer, S..

5 recordsLinked to original sources

Lysine acetylation plays a role in RNA binding protein-regulated alternative pre-mRNA splicing.

Alternative pre-mRNA splicing allows one gene to encode multiple spliced messenger RNAs and, in turn, multiple proteins from a single gene transcript. This process is tightly regulated by cis elements within the pre-mRNA and trans-acting RNA binding proteins that recognize and bind to these elements, thus influencing the spliceosome assembly at adjacent splice sites. Thus, chemical modifications in either the cis-elements or trans factors or both can significantly alter splicing patterns and, thereby, the cellular proteome. Recent studies highlight that many RNA binding proteins (RBPs) are modified at multiple lysine side chains via acetylation, which neutralizes the formal positive charge and disrupts RPBs ability to participate in RNA recognition, binding and protein-protein interactions. This suggests that lysine acetylation of RPBs may be a novel mode of eukaryotic gene regulation during pre-mRNA processing. To test this, we used the well-characterized polypyrimidine tract binding protein (which is acetylated at several lysine side chains) as a model system to investigate the role of reversible RBP acetylation in regulating alternative-pre mRNA splicing. Using multiple sequence analysis, structure-based electrostatic modeling of RNA-protein interactions, and multi-site glutamine (acetyllysine mimic) and arginine (deacetyllysine mimic) mutants, we show for the first time that for a subset of PTBP1-regulated exons, acetylation at RNA-interacting lysine side chains significantly alters PTBP1 splicing activity.

biochemistry↗

Clonal evolutionary analysis reveals patterns of malignant transformation in pancreatic cancer from Intraductal Papillary Mucinous IPMN Neoplasms (IPMN)

Intraductal papillary mucinous neoplasms (IPMNs) are critical precursors to pancreatic ductal adenocarcinoma (PDAC), a highly lethal cancer due to late detection and rapid progression. Using multi-region whole-genome and transcriptome sequencing, we traced the evolution of PDAC from IPMN, constructing detailed phylogenetic trees to provide insights into subclonal architectures and progression pathways. Our analysis identified two distinct evolutionary trajectories: one driven by a single ancestral clone, and another involving multiple independent ancestral clones, potentially influencing the timing and nature of PDAC onset. We further explored the roles of mutational signatures and structural variants (SVs) in promoting clonal evolution. Complementing these genomic findings, our transcriptomic analysis revealed unique gene expression profiles and variations in the immune landscape, correlating with the different progression stages from IPMN to PDAC. These insights reveal the complex molecular dynamics of IPMN progression to PDAC, highlighting the need to refine early detection and treatment strategies.

cancer biology↗

Carbapenem- and cefiderocol-resistant Enterobacterales in surface waters in Kumasi, Ashanti Region, Ghana

This study investigated the presence of extended-spectrum {beta}-lactamase-producing Enterobacterales in selected surface waters in the Ashanti Region in Ghana. Subsequent genomic analysis revealed that one-fifth of the isolates were genotypically carbapenem-resistant. Phenotypic susceptibility testing not only confirmed their carbapenem resistance, but also uncovered two cefiderocol-resistant isolates.

microbiology↗

Targeting DNA damage response and Replication Stress in Pancreatic Cancer

Continuing recalcitrance to therapy cements pancreatic cancer (PC) as the most lethal malignancy, which is set to become the second leading cause of cancer death in our society. We interrogated the transcriptome, genome, proteome and functional characteristics of 61 novel PC patient-derived cell lines to define novel therapeutic strategies targeting the DNA damage response (DDR) and replication stress. We show that patient-derived cell lines faithfully recapitulate the epithelial component of pancreatic tumors including previously described molecular subtypes. Biomarkers of DDR deficiency, including a novel signature of homologous recombination deficiency, co-segregates with response to platinum and PARP inhibitor therapy in vitro and in vivo. We generated a novel signature of replication stress with potential clinical utility in predicting response to ATR and WEE1 inhibitor treatment. Replication stress and DDR deficiency are independent of each other, creating opportunities for therapy in DDR proficient PC, and post-platinum therapy.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=145 SRC=\"FIGDIR/small/713545v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (47K):\norg.highwire.dtl.DTLVardef@106f2b8org.highwire.dtl.DTLVardef@1294d22org.highwire.dtl.DTLVardef@86f5d3org.highwire.dtl.DTLVardef@751e13_HPS_FORMAT_FIGEXP M_FIG C_FIG STATEMENT OF SIGNIFICANCEWe define therapeutic strategies that target subgroups of PC using novel signatures of DNA damage response deficiency and replication stress. This potentially offers patients with DNA repair defects therapeutic options outside standard of care platinum chemotherapy and is being tested in clinical trials on the Precision-Panc platform.

cancer biology↗

Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDA) is characterized by abundant infiltration of tumor associated macrophages (TAMs). TAMs have been reported to drive resistance to gemcitabine, the front-line chemotherapy in PDA, though the mechanism of this resistance remains unclear. Profiling metabolite exchange, we demonstrate macrophages programmed by PDA cells release a spectrum of pyrimidine species. These include deoxycytidine, which inhibits gemcitabine through molecular competition at the level of drug uptake and metabolism. Accordingly, genetic or pharmacological depletion of TAMs in murine models of PDA sensitizes these tumors to gemcitabine. Consistent with this, patients with low macrophage burden demonstrate superior response to gemcitabine treatment. Additionally, we report pyrimidine release is a general function of anti-inflammatory myeloid cells, suggesting an unknown physiological role of pyrimidine exchange by immune cells.

cancer biology↗